Morgan Stanley Cyclacel Pharmaceuticals, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $6 - $13	-12 Reduced 0.99%	1,200 $0
Q4 2022 Feb 14, 2023	BUY	$0.54 - $21.75 $6 - $261	12 Added 1.0%	1,212 $0
Q3 2022 Nov 14, 2022	BUY	$1.23 - $21.9 $1,476 - $26,280	1,200 New	1,200 $2,000
Q1 2022 May 13, 2022	SELL	$5.93 - $7.6 $200,208 - $256,591	-33,762 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.04 - $8.03 $473,892 - $630,025	-78,459 Reduced 69.91%	33,762 $131,000
Q3 2021 Nov 15, 2021	BUY	$8.02 - $11.0 $900,012 - $1.23 Million	112,221 New	112,221 $591,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $7.9M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.